Genetically engineered bacteria: a new frontier in targeted drug delivery

Area of Science:

• Biomedical Engineering
• Synthetic Biology
• Nanomedicine

Background:

• Genetically engineered bacteria (GEB) are explored for revolutionizing medicine due to properties like enhanced targeting, biodegradability, and self-amplification.
• GEB offer a promising alternative to synthetic systems for targeted drug delivery, with potential for cancer theranostics.
• Challenges in safety and controllability remain key areas for research and development.

Purpose of the Study:

• To review recent advances in the application of GEB for targeted drug delivery and cancer therapy.
• To discuss critical challenges and future perspectives in the field of GEB-based medicine.
• To highlight the potential of GEB in personalized medicine and bio- and nanomedicine.

Main Methods:

• Review of current literature on genetically engineered bacteria for drug delivery.
• Exploration of synthetic biology tools (e.g., CRISPR) and microbiome engineering.
• Discussion of biocontainment strategies and immune system interactions.

Main Results:

• GEB demonstrate unique advantages including targeted delivery, biodegradability, and reduced drug resistance.
• Novel tactics such as synthetic biology, microbiome engineering, and combination therapies are improving GEB capabilities.
• GEB show significant promise for personalized medicine, especially in cancer treatment.

Conclusions:

• GEB represent a vital tool for precise and controlled drug delivery, particularly in oncology.
• Future directions include integrating nanotechnology, microbiota-targeted therapies, and programmable behaviors.
• Ethical considerations and regulatory frameworks are crucial for the responsible development and application of GEB.